MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z
  • Tactile and proprioceptive dysfunction differentiates between cervical dystonia with and without tremor

    L. Avanzino, A. Cherif, O. Crisafulli, F. Carbone, A. Ravaschio, P. Morasso, J. Zenzeri, R. Marchese, G. Abbruzzese, E. Pelosin, J. Konczak (Genova, Italy)

  • Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography

    LFV. Vasconcellos, MS. Spitz, DN. Nassif, BRA. Andrade (Rio de Janeiro, Brazil)

  • Targeted deep sequencing of brain DNA for detection of somatic point mutations in synucleinopathies

    M. Leija-Salazar, A. Pittman, K. Mokretar, A. Schapira, C. Proukakis (London, United Kingdom)

  • Targeted NGS of genes related to hereditary and sporadic NDDs and movement disorders in Italian cohort

    G. Dati, M. Picillo, M. Ginevrino, A. Vallelunga, MT. Pellecchia, EM. Valente, P. Barone (Baronissi, Italy)

  • Task difficulty and the three-stimulus oddball task in patients with PD

    E. Peterson, R. Shoorangiz, R. Jones, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, R. Kuijer, T. Anderson, J. Dalrymple-Alford, B. Elias (Auckland, New Zealand)

  • Task Specific Dystonia and Its Response to Botulinum Neurotoxin Treatment

    R. Ortiz, T. Mertsalmi, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

  • Task-specific lower limb dystonia only during walking stairs

    JS. Baik, HI. Ma (Seoul, Republic of Korea)

  • Tau and amyloid-beta inclusions are present in pancreatic beta-cells of patients with synucleinopathies

    I. Martinez-Valbuena, R. Valenti-Azcarate, J. Sanchez, I. Marcilla Garcia, I. Amat-Villegas, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

  • Tau pathology is associated to cognitive and not motor function in Parkinson’s disease

    I. Liepelt-Scarfone, H. Vanderstichele, W. Maetzler, C. Francois, C. Schulte, M. Timmers, L. van Nueten, G. Salvadore, K. Brockmann, T. Gasser, J. Streffer, E. Stoops, D. Berg (Tübingen, Germany)

  • Technology-based assessment of motor impairment in de novo Parkinson’s disease patients: implications for diagnostic accuracy and early identification of distinct phenotypes

    G. Di Lazzaro, M. Ricci, T. Schirinzi, G. Saggio, NB. Mercuri, A. Pisani (Rome, Italy)

  • TELE PARK: Evaluation of the appropriation of a digitally guided self-rehabilitation device for patients with Parkinson’s disease and their professional entourage on a health territory in Brittany, France.

    E. Leblong, AL. Roy, B. Fraudet, A. Riou, A. Durufle, JF. Aubry, B. Nicolas, P. Gallien (Rennes, France)

  • Temporal Emergence of Symptoms and Functional Impairments in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

    F. Greblikas, HA. Jinnah, T. Klopstock, A. Videnovic, C. Burns (San Diego, CA, USA)

  • Texas Biorepository of Human Induced Pluripotent Stem Cells for Studying Parkinson’s Disease

    S. Wijemanne, H. Hong, G. Choudhury, J. Kim, J. Ramirez-Castaneda, A. Papanastassiou, M. Daadi (San Antonio, TX, USA)

  • TFEB-driven expression prevents neurodegeneration in a multiple system atrophy mouse model

    ML. Arotcarena, M. Bourdenx, N. Dutheil, ML. Thiolat, E. Doudnikoff, S. Dovero, A. Ballabio, PO. Fernagut, W. Meissner, E. Bezard, B. Dehay (Bordeaux, France)

  • The applicability of the Scale for Assessment and Rating of Ataxia (SARA) in toddlers

    S. Polet, A. Tadema, S. Hbrahimgel, M. Vanden Berg, M. Kuiper, R. Brandsma, D. Sival (Groningen, Netherlands)

  • The Association between Cognition and Balance in idiopathic Parkinson’s Disease

    SH. Jung, L. King, M. Mancini, P. Carlson-Kuhta, R. Morris, J. Nutt, F. Horak (Seoul, Republic of Korea)

  • The association between frailty and Parkinson’s in the ReSPOnD trial

    N. Smith, D. Gaunt, A. Whone, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

  • The association parkinsonism and psychotic symptom in neurosyphilis

    S. Nafia, N. Louhab, M. Chraa, N. Kissani (Marrakech, Morocco)

  • The carotid ultrasonography revealed vagus nerve atrophy of the patients with parkinsonism

    S. Abe, T. Hirato, H. Saiki (Osaka, Japan)

  • The Chinese Parkinson’s disease Registry scheme

    XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Q. Xu, Y. Tian, LJ. Fang, ZQ. Wang, QY. Sun, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

  • The Circulatory Levels of Serotonin, Beta endorphin and Dopamine and their relations to Pain Perception in People with Parkinson’s Disease

    H. Khalil, N. Al-Yahya, A. Al-Sharman, M. Alqudah, K. El-Salem (Irbid, Jordan)

  • The Clinical Features of Parkinson’s Disease with 20 Years or More Survival

    JJ. Lin, KC. Yueh (Nantou, Taiwan)

  • The Clinical, Molecular and Radiographic Spectrum of Adaptor Protein Complex 4-associated Hereditary Spastic Paraplegia (AP-4-HSP): Results from the AP-4-HSP International Registry

    J. Teinert, R. Behne, M. Wimmer, A. Diplock, E. Carmody, K. Dies, D. Jensen, J. Bennett, M. Sahin, D. Ebrahimi-Fakhari (Boston, MA, USA)

  • The cognitive profile associated with mild parkinsonian signs in a British Birth Cohort at age 69-71

    S. Buchanan, C. Lane, K. Lu, T. Parker, S. James, A. Keshavan, S. Keuss, H. Murray-Smith, A. Wong, D. Cash, W. Coath, S. Crutch, N. Fox, M. Richards, A. Schrag, J. Schott (London, United Kingdom)

  • The cognitive profiles differ among freezing of gait subtypes in Parkinson’s disease

    J. Longhurst, J. Caldwell, A. Ritter, V. Mishra, B. Bluett, M. Landers (Las Vegas, NV, USA)

  • The comparison of cognitive function between normal and abnormal FDG-PET in non-demented Parkinson’s disease

    SJ. Kim, EJ. Chung (Busan, Republic of Korea)

  • The comparison of the clinical characteristics and treatment outcomes between non-troublesome and troublesome hemifacial spasm in 270 Thai patients

    T. Sangpeamsook, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, P. Srivanitchapoom (Bangkok, Thailand)

  • The concept of a ‘long lesion’ in thalamic/Zona inserta DBS for MS tremor suppression

    S. Alusi, B. Hammersley, J. Somerset, P. Eldridge, J. Farah (Liverpool, United Kingdom)

  • The congruence of asymmetry between motor symptoms and retinal thickness in Parkinson’s disease

    W. Suh, JY. Hong, SY. Kang (Wonju, Republic of Korea)

  • The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease

    I. Rektor, B. Vesely, N. Bohnen, E. Koritakova, E. Kurca, P. Valkovic (Brno, Czech Republic)

  • The contribution of striatal dopamine to feedforward motor control during gait initiation in Parkinson’s disease

    G. Brandt, C. Palmisano, J. Brumberg, N. Pozzi, A. Canessa, G. Pezzoli, I. Isaias, J. Volkmann (Würzburg, Germany)

  • The costs of caregiving in Parkinson’s disease

    S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)

  • The development of a patient education and treatment programme for people with Parkinson’s disease

    P. Sloan, J. Farrell, J. Mchattie, L. Ebenezer, H. Evans (Bridgend, United Kingdom)

  • The differential role of subthalamic and nigral neurons in gait control in Parkinson´s disease patients

    A. Gulberti, M. Horn, J. Wagner, M. Schaper, J A. Koeppen, C. Buhmann, A. Sharott, M. Westphal, A K. Engel, C. Gerloff, W. Hamel, CKE. Moll, M. Pötter-Nerger (Hamburg, Germany)

  • The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis

    F. Gövert, J. Becktepe, B. Balint, J. Varley, S. Irani, M. Titulaer, J. de Vries, B. Joubert, J. Honnorat, H. Ariño Rodríguez, J. Dalmau, G. Deuschl, F. Leypoldt (Kiel, Germany)

  • The dopamine receptor antagonist haloperidol enhances beta and gamma oscillations and bursts in the motor cortex

    M. Alam, T. Doll, J. Krauss, K. Schwabe (Hannover, Germany)

  • The Dutch Parkinson and Cognition study (DUPARC): Cognitive impairment and cholinergic innervation in de novo Parkinson’s Disease patients

    S. Vander Zee, JM. Boertien, MJJ. Gerritsen, JM. Spikman, T. van Laar (Groningen, Netherlands)

  • The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients

    J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)

  • The Dutch Yips Study

    E. van Wensen, HJ. Vd Zaag, BP. Vd Warrenburg (Apeldoorn, Netherlands)

  • The Economic Burden of Parkinson’s Disease (PD) in the United States

    C. Tanner, R. Albin, N. Dahodwala, R. Dorsey, W. Yang, L. Schmiel, I. Cintina, C. Kopil, J. Beck, J. Hamilton (San Francisco, CA, USA)

  • The effect of active contact localization on motor symptoms in deep brain stimulation of the subthalamic nucleus for Parkinson’s disease

    T. Ten Brinke, V. Odekerken, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

  • The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease

    BC. Ari, F. Mayda Domac, G. Ozgen Kenangil, N. Imamova, A. Cinar Kuskucu (Istanbul, Turkey)

  • The effect of ATP13A2/PARK9 levels on a-syn spreading in mice brains

    T. Tsunemi, Y. Ishiguro, A. Okuzumi, A. Yoroisaka, N. Nukina, N. Hattori (Tokyo, Japan)

  • The effect of baseline cognitive status of Parkinson’s disease on the outcome after deep brain stimulation surgery

    KW. Park, NR. Choi, SY. Jo, MS. Kim, NE. Han, SR. Jeon, SJ. Chung (Seoul, Republic of Korea)

  • The effect of coexistent neurodegenerative disorders on the clinical features of idiopathic normal pressure hydrocephalus

    A. Hattori, T. Tsunemi, N. Hattori (Bunkyo-Ku, Japan)

  • The effect of dopaminergic therapy on functional connectivity in patients with Parkinson’s disease and visual hallucinations

    A. Powell, J. Shine, S. Lewis (Sydney, Australia)

  • The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

    R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

  • The effect of Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs on voluntary movements in adults with spastic hemiparesis

    J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)

  • The effect of intranasal oxytocin in patients with functional motor symptoms: an open label case series

    B. Demartini, D. Goeta, D. Di Benedetto, A. Casiraghi, D. Mazza, A. Priori, O. Gambini (Milano, Italy)

  • The effect of istradefylline on mood disorders in Parkinson’s disease

    H. Nagayama, O. Kano, H. Murakami, M. Hamada, R. Sengoku, Y. Shim, T. Toda (Tokyo, Japan)

  • The effect of Kinesio Taping therapy on Cervical Dystonia

    J. Magalhães, A. Rosso, F. Rezende (Rio de Janeiro, Brazil)

  • The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

    F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

  • The effect of Levodopa-Carbidopa Intestinal Gel on Non-Motor Symptoms, Specificly Autonomic Dysfunctions

    H. Ekmekci, M. Gültekin (Ankara, Turkey)

  • The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)

    E. Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

  • The Effectiveness of Rehabilitation Using Honda Walking Assist in Parkinson’s Disease Patients; The Gait Analysis by a Markerless Motion Capture System

    N. Kawashima, M. Iijima, T. Hamano, K. Nagami, M. Isogai, M. Komachi, T. Furukado, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

  • The effectiveness of two-weeks self-stretch based on post-isometric relaxation in Parkinson’s disease patients

    A. Zimin, D. Yusupova (Moscow, Russian Federation)

  • The Effects of Apomorphine infusion on Head ptosis, a case report

    O. Skogar (Stockholm, Sweden)

  • The Effects of Computer Based Cognitive Rehabilitation on working memory in patients with Parkinson’s disease: A Systematic Review

    A. Loekkegaard, M. Niemeijer, K. Svaerke (Copenhagen, Denmark)

  • The effects of exercise focused on ankle joint movement for postural instability in patients with Parkinson’s disease: A pilot study

    R. Taniuchi, T. Harada, T. Makino, S. Togashi, K. Matsukawa, T. Hoshii (Otake, Japan)

  • The effects of obstacle size and timing on prefrontal cortex activation in patients with Parkinson’s disease

    I. Maidan, T. Sharon, I. Kurz, H. Bernad-Elazari, S. Shustak, I. Galperin, N. Giladi, A. Mirelman, J. Hausdorff (Tel Aviv, Israel)

  • The effects of onabotulinum toxin on neurophysiological tests in patients with hemifacial spasm

    O. Kocak, A. Tokcaer (Ankara, Turkey)

  • The Effects of Time-Varying Caloric Vestibular Stimulation Therapy on Cognition Impairment in Parkinson’s Disease

    K. Ade, A. Podlewska, S. Banducci, T. Pellat-Higgins, M. Bodani, M. Sakel, L. Smith, D. Attix, P. Lewitt, D. Wilkinson (Raleigh, NC, USA)

  • The effects of timed exposure to bright light in improving the gait patterns of patients with Parkinson’s disease – A pilot study

    L. Alibiglou, T. Ruopp (Tehran, Islamic Republic of Iran)

  • The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

    K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

  • The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

    R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

  • The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials

    M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

  • The efficiency of group cognitive rehabilitation to patients with Parkinson’s disease in comparison to relaxation therapy: pilot data

    V. Plzáková, D. Enström, T. Nikolai (Prague, Czech Republic)

  • The evaluation of exosomes as a biomarker of Parkinson’s disease

    Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

  • THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON’S DISEASE

    N. Djebli (Mostaganem, Algeria)

  • The First Chinese Case of Fragile X-associated Tremor/ Ataxia Syndrome :an underestimated disease in China

    C. Zhao (Jinan, China)

  • The first tremor dominant Parkinson’s Disease treatment in Taiwan using MR-guided focused ultrasound

    HC. Lai, WK. Tsai, WC. Chang (Changhua County, Taiwan)

  • The French NS-PARK/FCRIN network: a 5-year balance sheet

    O. Rascol, JC. Corvol, F. Durif, E. Delappina, V. Chaigneau, JP. Azulay, P. Couratier, L. Defebvre, D. Devos, P. Damier, A. Doe, S. Drapier, S. Frismand, C. Geny, C. Giordana, JL. Houeto, P. Krystkowiak, E. Magnin, D. Maltete, W. Meissner, T. Moreau, E. Moro, P. Remy, C. Thiriez, S. Thobois, C. Tranchant, F. Viallet, M. Vidailhet (Paris, France)

  • The frequency and impact of mutations in the GBA gene and APOε4 polymorphisms on the clinical features of Dementia with Lewy Bodies among Ashkenazi Jews

    T. Shiner, A. Mirelman, Y. Rozenblum, G. Kave', M. Gana Weisz, A. Bar-Shira, A. Thaler, R. Shahar, T. Gurevich, A. Orr-Urtreger, N. Giladi, N. Bregman (Tel Aviv, Israel)

  • The frequency of lower urinary tract symptoms in patients with Parkinson’s disease and Clinical efficacy of istradefylline

    Y. Higashi, M. Tabata, T. Tabuchi (Himeji, Japan)

  • The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients

    N. Durmaz çelik, M. Kuzu Kumcu, S. Bostan, E. Yiğit Tekkanat, S. özkan (Eskisehir, Turkey)

  • The Genetic Basis of paediatric movement disorders: experience from the SYNaPS Study

    R. Maroofian, V. Salpietro, H. Houlden (London, United Kingdom)

  • The Genetic Landscape of Complex Childhood-Onset Hyperkinetic Movement Disorders

    M. Kurian, V. Leuzzi, K. Peall, R. Pons, R. Dale, E. de Grandis, S. Yilmaz, J. Cobben, R. Guerrini, E. Sheridan, P. Vieira, J. Uusimaa, P. Munot, F. Muntoni, M. Smith, S. Mohammed, E. Meyer, J. Ng, A. Papandreou, H. Baide, F. Danti, A. Macaya, J. Ortigoza, K. Gorman, B. Perez Duenas (Barcelona, Spain)

  • The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

    J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

  • The impact of clinical care coordination on patient quality of life in the Atypical Parkinsonism clinic

    M. Harris, J. Donnelly, L. Massey, B. Ghosh (Southampton, United Kingdom)

  • The impact of HIV on the severity and course of Parkinson’s disease: a clinical case

    A. Kudrevatykh, E. Gracheva, I. Miliukhina (St. Petersburg, Russian Federation)

  • The impact of medication and deep brain stimulation on visuo-motor coordination in Parkinson’s disease

    J. Daneault, A. Sadikot, B. Carignan, M. Panisset, C. Duval (Newark, NJ, USA)

  • The impact of non-motor symptoms on the quality of life of patients with Parkinson’s disease depending on its stages

    K. Abdurakhmonova, G. Rakhimbaeva (Tashkent, Uzbekistan)

  • The Impact of Parkinson’s Disease to Quality of Life

    R. Pinzon, RDL. Sanyasi (Yogyakarta, Indonesia)

  • The impact of physical activity and exercise on people living with dystonia

    L. Bradnam, R. Meiring, A. Mccambridge (Auckland, New Zealand)

  • The Impact of Progressive Supranuclear Palsy (PSP) Disease Severity on Caregivers

    T. Xie, X. Ye, J. de Courcy, K. Golden, Y. Bao, J. Zamudio, L. Chiodo, J. Morgan (Mettawa, IL, USA)

  • The Impact of Progressive Supranuclear Palsy (PSP) Disease Severity on Healthcare Resource Utilization (HCRU)

    T. Xie, X. Ye, J. de Courcy, J. Mellor, J. Zamudio, L. Chiodo, Y. Bao (Mettawa, IL, USA)

  • The Impact of the New Classification Criteria on the Incidence of Tremor Syndromes

    A. Avila, N. Caballol, A. Planas-Ballvé, MI. Gómez-Ruiz, M. Balagué-Marmaña, X. Cardona (Barcelona, Spain)

  • The Impact of Tourette Syndrome and Tic Disorders on Education, Occupational and Personal Life

    I. Malaty, D. Shineman, W. Deeb (Gainesville, FL, USA)

  • The influence of baseline body mass index on cognitive decline in Parkinson’s disease

    SY. Kang, HS. Yoo, SJ. Chung, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

  • The influence of deep brain stimulation on the Parkinson’s disease brain: functional improvement correlates with increased alpha2 and beta band functional connectivity

    L. Boon, W. Potters, A. Hillebrand, R. de Bie, M. Bot, R. Schuurman, C. Stam, F. van Rootselaar, H. Berendse (Amsterdam, Netherlands)

  • The influence of gender, associated neurological disorder and motive for polysomnography (PSG) in the manifestations of REM sleep behaviour disorder (RBD)

    P. Bugalho, M. Salavisa (Lisbon, Portugal)

  • The influence of physical activities on cognition in small group of Parkinson’s Disease patients

    J. Silva, M. Pereira, L. Piovesara, P. Azevedo, F. Cendes, A. D'Abreu, R. Guimarães (Campinas, Brazil)

  • The influence of relationship quality on health-related quality of life when coping with Parkinson’s disease: a mediation analysis

    M. Karlstedt, SM. Fereshtehnejad, D. Aarsland, J. Lökk (Huddinge, Sweden)

  • The Influence of Sociodemographic Factors on Post-DBS Impulse Control Symptom Severity in Parkinson’s Disease

    H. Combs, A. Strutt, J. Jimenez-Shahed, N. Niemann, A. Viswanathan, M. York (Houston, TX, USA)

  • The interaction between iron metabolism and inflammation in Parkinson´s disease: an in vivo and post mortem study

    A. Martín-Bastida, B. Tilley, T. Alireza, S. Gentleman, D. Dexter, R. Ward (London, United Kingdom)

  • The interplay between cholinergic activity, attention, and turning in Parkinson’s disease

    R. Morris, D. Martini, G. Mcbarron, M. Mancini, F. Horak (Portland, OR, USA)

  • The legacy of Charles David Marsden: A role model in the field of movement disorders

    G. Froehner, L. Zubko, M. Pedro Franco, A. Meira, F. Germinani, H. Teive (Curitiba, Brazil)

  • The Level of Neuroendocrine Hormones in Parkinson´s Disease and their Potential Role as Biomarkers : A Pilot Study

    J. Kauffmann, M. Unger, G. Giebel, D. Grün, K. Faßbender, M. Fousse (Homburg, Germany)

  • The long-term effect of continuous apomorphine treatment on camptocormia in Parkinson´s disease: a 24-months longitudinal open, prospective follow-up study

    K. Mensikova, M. Kaiserova, M. Vastik, M. Nevrly, S. Kurcova, P. Kanovsky (Olomouc, Czech Republic)

  • The longevity gene Klotho and its CSF protein profiles as modifier for Parkinson´s disease in a longitudinal study

    M. Zimmermann, S. Lerche, C. Schulte, I. Wurster, G. Machetanz, C. Deuschle, A. Hauser, T. Gasser, D. Berg, E. Schleicher, W. Maetzler, K. Brockmann (Tuebingen, Germany)

  • The management of Parkinson’s Disease during pregnancy: literature review, case series and multi-disciplinary input

    C. Young, R. Phillips, L. Ebenezer, R. Zutt, C. Mitchell, K. Peall (Cardiff, United Kingdom)

  • The mechanism of tremor-modulating properties of propranolol and primidone in essential tremor: A study with transcranial magnetic stimulation and eye blink classical conditioning paradigm

    K. Vogelnik, N. Prezelj, R. Perellon Alfonso, P. Klavžar, M. Gregorič Kramberger, D. Flisar, D. Georgiev, Z. Pirtošek, M. Kojović (Ljubljana, Slovenia)

  • The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

  • The neural representations of the voice tremor spectrum

    L. Xavier, K. Simonyan (Boston, MA, USA)

  • The Nigeria Parkinson Disease Registry

    O. Ojo, S. Abubakar, K. Wahab, O. Olugbo, E. Nwazor, O. Oshinaike, A. Bello, U. Williams, O. Ekenze, N. Okubadejo, NPD. Collaborators (Idi-Araba, Nigeria)

  • The optimal connectivity profile of thalamic deep brain stimulation electrodes to effectively treat Essential Tremor

    B. Al-Fatly, S. Ewert, D. Kuebler, D. Kroneberg, A. Horn, A. Kuehn (Berlin, Germany)

  • The Oral Metagenome and Metatranscriptome of Early Stage Parkinson’s Disease and their Relationship with Clinical and Functional Outcome Measures of Motor and Nonmotor Function

    D. Mihaila, J. Donegan, M. Vidal, D. Larocca, R. Ericson, S. Barns, C. Neville, R. Uhlig, F. Middleton (Syracuse, NY, USA)

  • The origin of stimulation-induced dysarthria in ET patients after VIM/PSA-DBS: Atactic, spastic or both?

    H. Jergas, J. Petry-Schmelzer, J. Becker, T. Thies, J. Steffen, V. Visser-Vandewalle, T. Dembek, M. Barbe (Cologne, Germany)

  • The P3a wave and cognitive decline in relation to Parkinson’s disease severity

    G. Sánchez Dinorín, M. Rodríguez Violante, A. Cervantes Arriaga, C. Navarro Roa, R. Solís Vivanco (Mexico City, Mexico)

  • The physiologic complexity of hand tremor identifies Parkinsonian tremor and essential tremor

    D. Su, Z. Liu, H. Pan, T. Feng, J. Zhou (Beijing, China)

  • The PLA2G6 Gene Mutation Causes Parkinson’s Disease: A Case Report

    L. Kou, T. Wang, L. Liu, GX. Zhang (Wuhan, China)

  • The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers

    JM. Laffita-Mesa, CH. Kreidy, M. Paucar, P. Svenningsson (Stockholm, Sweden)

  • The Power of Normal Saline in Reducing Skin Nodules in Apomorphine

    F. Leen, A. Evans, T. Canento, M. Ghaly, C. Wools, B. Cruse, M. Beckley (Melbourne, Australia)

  • The Preferences of Patients with Parkinson’s Disease and their Family Members for Place of End-of-Life Care

    R. Kozáková, R. Bužgová, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

  • The prevalence and features of REM sleep behaviour disorder in Essential Tremor: a polysomnography study

    P. Bugalho, M. Salavisa, C. Borbinha, M. Fernandes, B. Meira, R. Barbosa, M. Mendonça (Lisboa, Portugal)

  • The Prevalence of Essential Tremor in Edirne and Its Districts Concomitant Comorbid Conditions

    S. Güler, A. Caylan, N. Turan (Edirne, Turkey)

  • The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis

    P. Barbosa, A. Lees, A. Djamshidian, T. Warner (Innsbruck, Austria)

  • The prevalence of supine hypertension and nocturnal hypertension and the difference of blood pressure in each sleep position in Parkinson’s disease

    J. Sringean, R. Hamindra, R. Bhidayasiri (Bangkok, Thailand)

  • The progression rate of sporadic adult-onset cerebellar ataxia : 1-year follow up study

    PW. Ko, HW. Lee, K. Kang (Daegu, Republic of Korea)

  • The Progressive Supranuclear Palsy Functional Disability Scale: Sensitivity to change

    I. Piot, K. Schweyer, G. Respondek, M. Grimm, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, G. Stebbins, G. Höglinger (Munich, Germany)

  • The Promise of Automation: Development and preliminary testing of a language-based machine learning algorithm in PD

    B. Fujii, R. Richter, A. Roberts (Evanston, IL, USA)

  • The proportion of patients with early-onset Parkinson’s disease: a systematic review and meta-analysis

    G. Nepal (Kathmandu, Nepal)

  • The radiofrequency (RF)-induced heating profile of an externalized, directional DBS lead using functional imaging sequences in an Intraoperative Magnetic Resonance Imaging Suite (IMRIS)

    P. Bhattacharyya, S. Jones, M. Lowe, M. Deblock, A. Machado, K. Baker (Cleveland, OH, USA)

  • The relationship between brain edema after deep brain stimulation surgery and the function of motor and cognition

    Y. Nishiguchi, K. Matsuura, S. Sakano, Y. Hirata, A. Mizutani, N. Katoh, A. Ito, K. Tachibana, H. Ishikawa, K. Miyashita, T. Utsunomiya, H. Kajikawa, T. Yamanaka, H. Nishikawa, T. Araki, H. Tomimoto (Tsu-Shi, Mie, Japan)

  • The relationship between constipation and alteration of gut microbiota in patients with Parkinson’s disease

    BI. Zao An, M. Ye (Nanjing, China)

  • The relationship between sound pressure level (SPL) and speech intelligibility in Parkinson’s disease following intensive speech treatment: LSVT LOUD and LSVT ARTIC

    L. Ramig, E. Levy, M. Chang, K. Forrest, G. Moya-Gale (Boulder, CO, USA)

  • The relationship between the motor onset and the asymmetry of motor symptoms in patients with Parkinson’s Disease

    Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

  • The Relationship of Neuropsychiatric Symptoms and Cognitive Impairment in Parkinson’s Disease

    B. Bernard, G. Stebbins, A. Negron, D. Merkitch, J. Goldman (Chicago, IL, USA)

  • The relationship of non-motor symptoms with the dominant symptom and the stage of patients with Parkinson’s disease

    E. Tur, M. Demir, G. Kenangil (Istanbul, Turkey)

  • The Representativity of PSP patients included in clinical trials

    LL. Mariani, R. Guimarães-Costa, D. Grabli, B. Letoullec, F. Cormier, B. Degos, B. Dubois, M. Vidailhet, L. Lacomblez, JC. Corvol (Paris, France)

  • The right hemisphere inhibitory network in patients with asymmetrical Parkinson’s disease: An fMRI study

    F. Lazoya, I. Obeso, R. Gonzales Redondo, F. Villagra, E. Luis, J. Obeso, M. Jahanshahi, M. Pastor (Pamplona, Spain)

  • The Roche HD Natural History Study – an external comparator by design

    G. Hooper, G. Palermo, F. Hlavac, C. Finnegan, E. Frick, L. Boak, R. Doody, S. Schobel (Welwyn Garden City, United Kingdom)

  • The role of attention in functional movement disorders

    A. Huys, P. Haggard, K. Bhatia, M. Edwards (London, United Kingdom)

  • The role of Dopamine in Preparatory Inhibition: What can we learn from Parkinson’s disease?

    E. Wilhelm, C. Quoilin, G. Derosiere, A. Jeanjean, J. Duqué (Brussels, Belgium)

  • The role of dysfunctional attentional processing in isolated minor hallucinations in Parkinson’s disease

    H. Bejr-Kasem, J. Pagonabarraga, S. Martínez-Horta, F. Ruiz-Martínez, F. Bernasconi, F. Sampedro, J. Marín-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, B. Pascual-Sedano, O. Blanke, J. Kulisevsky (Barcelona, Spain)

  • The Role of Dysfunctional BDNF in Remodeling the Parkinsonian Striatum Following Dopamine Neuron Grafting in CRISPR rs6265 Rats

    N. Mercado, J. Stancati, T. Collier, C. Sortwell, I. Sandoval, C. Kemp, B. Daley, M. Duffy, K. Steece-Collier (Grand Rapids, MI, USA)

  • The Role of Environmental Toxins (Rotenone) in Parkinson’s Disease

    Z. Akbarkhodjaeva, DJ. Tursunov (Tashkent, Uzbekistan)

  • The role of genetic modifiers in Parkinson’s disease-associated LRRK2-G2019S mutation

    T. Courtin, G. Ianello, H. Bertrand, S. Benromdhan, C. Tesson, C. Mhiri, JC. Corvol, S. Lesage, A. Brice (Paris, France)

  • The role of lipid metabolism in mouse models of Parkinson’s disease

    M. Trabjerg, D. Andersen, P. Huntjens, K. Mørk, M. Skjønnemand, M. Oklinski, A. Mørkholt, I. Huijbers, C. Pritchard, L. Kroese, J. Nieland (Aalborg, Denmark)

  • The role of LRP10 mutations in Parkinson’s Disease and Dementia with Lewy Bodies

    A. Manini, E. Monfrini, L. Straniero, M. Vizziello, G. Franco, S. Duga, A. Di Fonzo (Milan, Italy)

  • The role of mitochondria in modifying penetrance of Parkin gene variants

    M. Castelo, J. Trinh, A. Zanon, J. Rainer, P. Bauer, K. Kandaswamy, M. Werber, A. Rolfs, A. Grunewald, M. Borsche, K. Lohmann, C. Klein, P. Pramstaller, I. Pichler, A. Hicks (Bolzano, Italy)

  • The role of Parkinson’s disease-associated RHOT1/Miro1 variants in mitochondrial dysfunction and impaired cellular quality control

    A. Chemla, C. Berenguer-Escuder, F. Massart, P. Seibler, C. Klein, D. Grossmann, A. Grünewald, R. Krüger (Belvaux, Luxembourg)

  • The role of stress-related genes and childhood trauma in the clinical phenotype of Functional Movement Disorders

    P. Spagnolo, C. Maurer, G. Norato, C. Hodgkinson, M. Hallett (Bethesda, MD, USA)

  • The role of Synaptic vesicle protein 2A (SV2A) in patients with Parkinson’s disease dementia and Dementia with Lewy bodies: An in vivo [11C]UCB-J PET study

    H. Wilson, G. Dervenoulas, G. Pagano, A. Chandra, F. Niccolini, M. Esposito, R. Gunn, L. Ricciardi, E. Rabiner, D. Aarsland, M. Politis (London, United Kingdom)

  • The role of the cerebellum in the pathophysiology of cortical myoclonus: a neurophysiological study.

    A. Latorre, L. Rocchi, G. Paparella, N. Manzo, A. Berardelli, J. Rothwell, K. Bhatia (London, United Kingdom)

  • The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease

    I. Miliukhina, E. Ermolenko, E. Gracheva, A. Istomina, M. Kotyleva, E. Agapova, A. Suvorov (Saint-Petersburg, Russian Federation)

  • The role of X-chromosome inactivation in the penetrance of X-linked dystonia-parkinsonism in women

    CJ. Reyes, R. Ardicoglu, R. Rosales, RD. Jamora, CC. Diesta, K. Grütz, H. Pawlack, A. Domingo, C. Klein, A. Westenberger, N. Brüggemann (Lübeck, Germany)

  • The Sequelae of Kernicterus

    Z. Aldaajani, E. Ali (Dhahran, Saudi Arabia)

  • The severity of motor dysfunctions and autonomic dysfunctions are not correlated in multiple system atrophy

    T. Yamamoto, Y. Yamanaka, A. Sugiyama, S. Hirano, T. Uchiyama, M. Asahina, R. Sakakibara, S. Kuwabara (Chiba, Japan)

  • The short-term effect of combined facial exercise with botulinum toxin A injection in clinical practice in Thai patients with hemifacial spasm: A randomized controlled pilot crossover study

    P. Soontrapa, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, T. Sangpeamsook, P. Srivanitchapoom (Bangkok, Thailand)

  • The social interaction in patients with Parkinson’s disease from the points of activities of daily living and motor function

    A. Kumon, M. Sagawa, M. Saruwatari, N. Kawashima, K. Hasegawa (Fujisawa, Japan)

  • The spectrum of involuntary vocalizations in humans

    T. Mainka, B. Balint, F. Gövert, L. Kurvits, C. van Riesen, A. Kühn, M. Tijssen, A. Lees, K. Müller-Vahl, K. Bhatia, C. Ganos (London, United Kingdom)

  • The statement about the effectiveness of non-medication methods in the complex treatment of spasticity of different genesis

    O.. Tondiy (Kharkiv, Ukraine)

  • The STN Sweet Spot for Tremor Control in Parkinson’s Disease

    T. Stiep, A. Diaz, I. Cajigas, J. Jagid, C. Luca (Miami, FL, USA)

  • The study on brain function network of Parkinson’s disease with depression

    Y. Qiu, L. Wang (Guangzhou, China)

  • The SUNRISE-PD Study, a clinical trial of AXO-LENTI-PD: a CNS-directed gene therapy for the treatment of Parkinson’s Disease

    G. Corcoran, P. Korner, J. Wright, Y. Mo, J. Benoit, K. Binley, J. Miskin, N. Tuckwell, D. Zamoryakhin, T. Foltynie, R. Barker, K. Mitrophanous, S. Palfi (New York, NY, USA)

  • The trace of substantia nigra hyperechogenicity: a clinical observation

    A. Alonso-Canovas, JL. Sendon-Moreno, G. Garcia-Ribas, N. Monterde-Gonzalez, C. Jara-Laguna, JC. Martinez-Castrillo, J. Masjuan (Madrid, Spain)

  • The ultrasonographic assessment of vagus nerve atrophy comparison with autonomic dysfunction in Parkinson’s disease

    T. Hirato, S. Abe, H. Saiki (Kita-Ku, Osaka, Japan)

  • The ultrasound image of the nuclei raphes changes in the group of depressed patients with cervical dystonia and blepharospasm

    AK. Krzak-Kubica, JG. Gawryluk, MD. Doręgowska, KP. Plinta, MR. Rudzińska-Bar (Katowice, Poland)

  • The Urge to Move in Restless Legs Syndrome Associated with Parkinson’s Disease: A Motor Impulse Control Disorder?

    A. Marques, C. Lambert, T. Vidal, F. Durif, M. Fantini (Clermont-Ferrand, France)

  • The Use of Diffusion Weighted Imaging to Detect Structural Biomarkers in Recently-Diagnosed Parkinson’s Disease Patients

    P. Macdonald, N. Handfield-Jones, E. Alushaj, N. Hiebert, A. Owen, A. Khan (London, ON, Canada)

  • The Use of Exergames in Neurorehabilitation in People with Parkinson’s Disease: Its Impact on Daily Life

    B. Zeigelboim, H. Teive, M. Severiano, G. Dos Santos, M. da Rosa, M. José, R. Sampaio, J. Malisky (Curitiba, Brazil)

  • The utility of DCTclock™ (the digital clock drawing test) for unmasking early cognitive decline in Parkinson’s disease

    T. Schejter Margalit, R. Kizony, B. Cohen, A. Thaler, W. Souillard-Mandar, A. Holway, V. Irzhevsky, A. Orr-Urtreger, J. Cederbaum, N. Giladi, A. Mirelman (Tel Aviv, Israel)

  • Therapeutic intervention of LRRK2 kinase inhibitors in Vps35 p.D620N Parkinsonism

    I. Tatarnikov, J. Follett, J. Fox, M. Farrer (Vancouver, BC, Canada)

  • Therapeutic management of complicated Parkinson’s disease: clinical application of the Motor Fluctuation Indices

    R. Bonomo, G. Mostile, A. Nicoletti, M. Zappia (Catania, Italy)

  • Think of Gluten Ataxia:A rare but potentially reversible cause of progressive neurological disorder

    R. Mathur, K. Lal, A. Kyi (Grantham, United Kingdom)

  • THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)

    S. Shrewsbury, J. Campbell, M. Swardstrom, A. Lehn, K. Satterly, J. Hoekman (Seattle, WA, USA)

  • Three cases of early tremor in the course of Guillain-Barré Syndrome

    S. Ten Holter, M. Louter, F. Eftimov, J. Dijk (The Hague, Netherlands)

  • Three-dimensional gait analysis of the effect of directional steering in Parkinson’s disease

    S. Sekimoto, G. Oyama, K. Bito, M. Tsuchiya, S. Kikuchi, B. Takimoto, T. Ichihashi, J. Bautista, M. Nuermaimaiti, F. Sasaki, R. Nakamura, T. Hatano, Y. Shimo, H. Iwamuro, M. Ito, A. Umemura, N. Hattori (Bunkyo-Ku, Japan)

  • Three-year follow-up of a patient with a rare combination of taupathy (PSP) and synucleopathy (MSA)

    D. Aygun (Samsun, Turkey)

  • Tic Detector – Role of Electromyography

    W. Deeb, S. Cernera, A. Gunduz, M. Okun (Gainesville, FL, USA)

  • Time-Frequency analysis of Gait-EEG signals for freezing of gait in a PD patient

    J. Li, Y. Zhang (Beijing, China)

  • Tissue Engineered Nigrostriatal Pathway as an Anatomically-Inspired Test-Bed for Evaluating Axonal Pathophysiology

    E. Clark, L. Struzyna, W. Gordian-Velez, I. Chen, J. Duda, D.K. Cullen (Philadelphia, PA, USA)

  • To compare early / late onset MSA from the PAN American MSA (PANMSA) database

    M. Cesarini, E. Gatto, J. Etcheverry, G. da Prat, F. Peralta (Caba, Argentina)

  • To respond or not to respond to paired associative stimulation: proof of intervention by cerebello-cortical circuit

    A. Kishore, P. James, P. Rajeswari, A. Thejaus, G. Sarma, S. Meunier (Trivandrum, India)

  • Tongue Myokymia and Earache as a unique presentation Associated with Local Tongue Pathology: A Case Report and Review of Literature

    N. Merghany, W. Ibrahim, S. Nasr (Cairo, Egypt)

  • Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease

    G. Beck, H. Mochizuki, S. Papa (Atlanta, GA, USA)

  • Touching Nose: Alleviating Maneuvers (Sensory Tricks) in Orofacial Dystonia

    NG. Bülbül, MG. şenol (Istanbul, Turkey)

  • Towards unobtrusive Parkinson’s disease detection via motor symptoms severity inference from multimodal smartphone-sensor data

    D. Iakovakis, S. Hadjidimitriou, V. Charisis, K. Kyritsis, A. Papadopoulos, M. Stadtschnitzer, H. Jaeger, I. Dagklis, S. Bostantjopoulou, Z. Katsarou, L. Klingelhoefer, S. Mayer, R. Reichmann, D. Trivedi, A. Podlewska, A. Rizos, K. Chaudhuri, A. Delopoulos, L. Hadjileontiadis (Thessaloniki, Greece)

  • TPK1 mutation induced childhood onset dystonia and dyskinesia

    L. Au, A. Chan, C. Lau, V. Mok (Hong Kong, Hong Kong)

  • Tracking cortical changes throughout cognitive decline in Parkinson’s disease: a longitudinal MRI study

    E. Canu, F. Agosta, T. Stojković, S.. Basaia, I. Stankovic, V. Markovic, I. Petrović, E. Stefanova, V. Kostic, M. Filippi (Milan, Italy)

  • Tractography-based targeting of the ventral intermediate nucleus for asleep DBS implantation

    C. Matias, M. Alizadeh, J. Muller, A. Sharan, C. Wu (Philadelphia, PA, USA)

  • Training and Usage of Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

    R. Bhidayasiri, K. Bhatia, LJ. Jacinto, TM. Chung, A. Fulford-Smith, C. Colosimo (Roma, Italy)

  • Transcranial Direct Current Stimolation (tDCS) on PD Patients with Freezing of Gait: Preliminary Findings

    S. Scalise, G. Di Lazzaro, M. Alwardat, NB. Mercuri, M. Patera, G. Saggio, T. Schirinzi, A. Pisani (Rome, Italy)

  • Transcranial MR guided FUS thalamotomy in essential tremor: a comprehensive lesion characterization

    D. Urso, J. Pineda-Pardo, R. Martínez-Fernández, R. Rodríguez-Rojas, M. Del-Alamo, P. Millar-Vernetti, JU. Mañez, F. F. Hernández-Fernández, E. de Luis-Pastor, L. Vela, JA. Obeso (Móstoles, Spain)

  • Transcranial neuromodulation of the Frontal Eye Fields: targeting Temporal Discrimination Thresholds (TDT) in Adult Onset Primary Torsion Dystonia (AOPTD)

    O. Killian, I. Ndukwe, S. Narasimham, S. O'Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

  • Transcranial Photobiomodulation as an adjunct to Levodopa therapy in patients with Parkinson’s Disease; an open label pilot study

    H. Singh, N. Sawal (Chandigarh, India)

  • Transcranial sonography in carriers of Gaucher disease

    F. Omrani, N. Mohammadzade, M. Rohani, Z. Omrani, B. Zamani (Tehran, Islamic Republic of Iran)

  • Transcranial ultrasound in atypical parkinsonism: how reliable is it in real clinical practice? A multi-centre comprehensive study

    A. Alonso-Canovas, JI. Tembl-Ferrairo, I. Martinez Torres, JL. Lopez Sendon-Moreno, I. Parees-Moreno, E. Monreal-Laguillo, P. Perez-Torre, R. Toledano, G. Garcia-Ribas, J. Masjuan, JC. Martinez-Castrillo, U. Walter (Rostock, Germany)

  • Transcriptome modification of anodal transcranial direct current stimulation in transgenic Parkinson’s disease mouse model

    W. Jang, H-T. Kim (Seoul, Republic of Korea)

  • Transient orthostatic blood pressure changes in Parkinson’s Disease: impact on falls, syncope and orthostatic intolerance

    A. Fanciulli, N. Campese, G. Goebel, J. Ndayisaba, S. Eschlboeck, C. Kaindlstorfer, C. Raccagni, R. Granata, U. Bonuccelli, R. Ceravolo, W. Poewe, G. Wenning (Innsbruck, Austria)

  • Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

    M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

  • Translation of a subject-specific stereotaxic platform to a large animal deep brain stimulation research models

    F. Paiva, B. Campbell, A. Martin, L. Frizon, A. Maldonado, A. Machado, K. Baker (Cleveland, OH, USA)

  • Translation, validation, diagnostic accuracy and reliability of a Parkinson´s disease screening questionnaire in three countries in Africa: A progress report and preliminary data

    NU. Okubadejo, A. Shalash, J. Doumbe, C. Tanner, R. Walker, C. Dotchin, OP. Agabi, E. Hamid, A. Helmi, H. Elrassas, T. Rushdi, O. Ojo, O. Oguntunde, S. Calvo, L. Aguado, E. Cubo (Burgos, Spain)

  • Treating Depression in Parkinson’s Disease: a Systematic Literature Review

    C. Farrell, T. Yousaf, M. Politis (London, United Kingdom)

  • Treatment approaches for infection following DBS

    F. Yuzbasi, H. Kaptan (Izmir, Turkey)

  • Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

    J. Wang, C. Battioui, Y. Li, A. Calvin, L. Wu, A. Romano, B. Miller (Indianapolis, IN, USA)

  • Treatment of dopaminergic augmented RLS with Ecopipam, A D1 specific antagonist: an exploratory placebo controlled cross-over trial

    O. Titlayo, W. Ondo (Houston, TX, USA)

  • Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

    RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)

  • Tremor and parkinsonism in Chromosomopathies – a systematic review

    V. Carvalho, L. Guedes (Matosinhos, Portugal)

  • Tremoroton, a new open source tool for tremor analysis

    F. Vial, P. Kassavetis, M. Hallett (Bethesda, MD, USA)

  • Trends in first line therapy for PD in Wales: A 16 year observational study

    K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

  • Trihexyphenidyl-induced chorea in a patient with spastic torticollis: A case report

    H. Kawasaki, O. Oota, S. Seo, K. Kei, T. Mistufuji, K. Takahashi, N. Tamura, T. Yamamoto (Moroyama, Japan)

  • Trust the Patient’s Report, not the Doctor’s: Non-Motor Symptoms and Quality of Life in Cervical Dystonia

    I. Ndukwe, J. Dover, P. Lynch, C. O'Neill, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

  • Tsallis entropy of EEG correlates with future cognitive decline in patients with Parkinson’s disease

    SM. Keller, A. Meyer, JG. Bogaarts, U. Gschwandtner, P. Fuhr, V. Roth (Basel, Switzerland)

  • TUBB4A mutation: Expansion of H-ABC phenotype with apparent iron accumulation in the basal ganglia – case report and literature review

    C. Gorodetsky, I. Tein (Toronto, ON, Canada)

  • Tumor Pathology in Patients with Huntington’s Disease in a Specialized Center of Buenos Aires, Argentina (Preliminary Data)

    D. Dias, E. Gatto, J. Etcheverry, M. Cesarini, G. da Prat, F. Peralta Calderon (Capital Federal, Argentina)

  • Turkish Version of the Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLS-QOL): Validity and Reliability Study

    S. Güler, N. Turan (Edirne, Turkey)

  • Two heterozygous SNYE1 mutations presenting as spasmodic adductor dysphonia, task-specific jaw dystonia, generalized dystonia, and ataxia in a Jamaican man

    E. Feinstein, P. Surathi (Newark, NJ, USA)

  • Two novel ANO10 mutations causing adult-onset autosomal recessive spinocerebellar ataxia

    B. Bergmans, S. Donatello, M. Pandolfo, C. Depondt (Brugge, Belgium)

  • Two Patients with Dopamine Transporter Deficiency Treated with Deep Brain Stimulation

    J. Maclean, D. Ferman, T. Sanger, A. Tongol (Los Angeles, CA, USA)

  • Two-year outcome of autologous peripheral nerve grafting to the substantia nigra at the time of DBS surgery in patients with Parkinson’s disease

    C. van Horne, J. Quintero, J. Slevin, J. Gurwell, Z. Guduru, A. Welleford, N. El Seblani, G. Gerhardt (Lexington, KY, USA)

Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley